PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS
申请人:Heer Jag Paul
公开号:US20130072499A1
公开(公告)日:2013-03-21
The present invention relates to novel piperazine compounds; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Ca
v
2.2 calcium channels is beneficial and to treat diseases for which blocking the Ca
v
2.2 and Ca
v
3.2 calcium channels is beneficial, e.g. to treat pain.
本发明涉及新型哌嗪化合物;含有这些化合物的药物组合物;以及利用这些化合物在治疗中治疗阻断Ca
v
2.2钙通道有益的疾病,以及治疗阻断Ca
v
2.2和Ca
v
3.2钙通道有益的疾病,例如治疗疼痛。
[EN] PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS<br/>[FR] DÉRIVÉS DE PIPÉRAZINE POUR BLOQUER DES CANAUX CALCIQUES CAV2.2
申请人:CONVERGENCE PHARMACEUTICALS
公开号:WO2011086377A1
公开(公告)日:2011-07-21
The present invention relates to novel piperazine compounds; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial and to treat diseases for which blocking the Cav2.2 and Cav3.2 calcium channels is beneficial, e.g. to treat pain.
Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds.
This invention provides, among other things, compounds useful for treating diseases such as fibrosis and/or cancer, pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.
[EN] BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS<br/>[FR] COMPOSÉS BENZOXAZOLINONE AYANT UNE ACTIVITÉ SÉLECTIVE DANS LES CANAUX SODIQUES POTENTIEL-DÉPENDANTS
申请人:MERCK SHARP & DOHME
公开号:WO2014066490A1
公开(公告)日:2014-05-01
Disclosed are compounds of Formula A: Formula A, or a salt thereof, wherein "Het", Ra, and Rb are defined herein, which have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating neuropathic pain disorders using the same.